https://swarmoncology.bio/ https://swarmoncology.bio/contact https://swarmoncology.bio/careers https://swarmoncology.bio/team https://swarmoncology.bio/news https://swarmoncology.bio/technology https://swarmoncology.bio/policy https://swarmoncology.bio/job-policy https://swarmoncology.bio/careers/senior-development-scientist https://swarmoncology.bio/cookie https://swarmoncology.bio/news/swarm-oncology-appoints-bernhard-ehmer-as-chairman https://swarmoncology.bio/news/scalereadytm-in-collaboration-with-wilson-wolf-manufacturing-bio-techne-corporation-(nasdaq-tech)-and-cellreadytm-today-(25th-september-2024)-announced-that-it-has-awarded-a-200-000-g-rex-grant-to-swarm-oncology-ltd-a-start-up-company-focusing-on-developing-cancer-neoantigen-vaccine-specific-t-cell-therapies-for-a-range-of-major-indications-including-head-and-neck-breast-and-colorectal-cancers.-this-grant-will-support-swarm-oncology%E2%80%99s-ongoing-program-of-development-and-manufacturing-of-its-antigen-specific-t-cell-platform-using-the-g-rex-flask-technology.-the-200-000-grant-will-support-both-manufacturing-process-optimizations-and-process-validations-by-cdmo-over-the-next-18-months-in-the-lead-towards-the-first-phase-i-clinical-trial-in-2026.-dr.-alasdair-fraser-director-for-r-d-commented-%E2%80%9Cwe-are-hugely-grateful-for-this-substantial-investment-into-our-process-development-and-manufacturing-validation-by-scaleready-especially-as-we-move-towards-our-planned-phase-i-clinical-trial.-wilson-wolf-has-also-provided-invaluable-advice-in-terms-of-optimising-the-g-rex-products-for-our-process.-this-kind-of-investment-demonstrates-their-commitment-to-building-better-cell-therapies-which-will-improve-the-outlook-for-cancer-patients-in-the-future.%E2%80%9D-about-scaleready%E2%84%A2-scaleready-provides-the-field-of-cell-and-gene-modified-cell-therapy-(cgt)-with-a-g-rex-centric-manufacturing-platform-that-enables-the-world-s-most-practical-flexible-scalable-and-affordable-cgt-drug-product-development-and-manufacturing.-the-g-rex-manufacturing-platform-is-currently-used-by-a-rapidly-growing-list-of-over-800-organizations-and-is-producing-drug-products-for-approximately-50-of-cgt-clinical-trials-as-well-as-4-commercially-approved-cgt-drugs.-cgt-entities-relying-on-the-breadth-and-scope-of-scaleready-s-expertise-can-expect-to-save-years-of-time-and-millions-of-dollars-on-the-path-to-cgt-commercialization.-for-more-information-about-the-scaleready-g-rex%C2%AE-grant-program-please-contact-info-scaleready.com.-about-wilson-wolf-manufacturing-corporation-wilson-wolf-(www.wilsonwolf.com)-is-dedicated-to-simplifying-cell-and-gene-modified-cell-(cgt)-therapy-research-process-development-and-manufacturing.-this-is-being-accomplished-through-its-scalable-g-rex%C2%AE-technology-which-is-used-throughout-the-world-in-cgt-applications-ranging-from-basic-research-to-commercial-drug-production.-wilson-wolf-s-mission-is-to-create-hope-for-cancer-patients-one-g-rex%C2%AE-device-at-a-time.-about-bio-techne-corporation-bio-techne-corporation-(nasdaq-tech)-is-a-global-life-sciences-company-providing-innovative-tools-and-bioactive-reagents-for-the-research-and-clinical-diagnostic-communities.-bio-techne-in-partnership-with-wilson-wolf-is-creating-products-such-as-media-and-cytokines-that-are-specifically-tailored-to-g-rex%C2%AE-bioreactors-including-right-sized-reagent-quantities-in-containers-that-are-tailored-to-high-throughput-closed-system-manufacturing.-for-more-information-on-bio-techne-and-its-brands-please-visit-https-www.bio-techne.com-or-follow-the-company-on-social-media-at-facebook-linkedin-twitter-or-youtube. https://swarmoncology.bio/news/research-collaboration-announcement https://swarmoncology.bio/news/martin-ceo https://swarmoncology.bio/news/john-presents-at-atw-2024 https://swarmoncology.bio/news/cellex-cdmo-announcement